Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 1/20 | 0.35 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.35 |
| ▸ | HTR3B | O95264 | 1/20 | 0.35 |
| ▸ | HTR3A | P46098 | 1/20 | 0.35 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.35 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 6/20 | 0.32 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.32 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.31 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.31 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1071132 | 0.90 | HTR3E (0.37) | STING1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL2897227 | 0.87 | HTR3E (0.36) | STING1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL3496689 | 0.85 | HTR3E (0.32) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL3496701 | 0.85 | HTR3E (0.32) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL12934499 | 0.84 | P2RX3 (0.39) | EGFRPIK3CDPIK3CAPIK3CGPIK3CB | |
| SCHEMBL2897360 | 0.83 | SMN1; SMN2 (0.40) | STING1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL3497319 | 0.82 | — | — | |
| SCHEMBL3497308 | 0.82 | — | — | |
| Hydrochloric Acid SCHEMBL2897201 | 0.80 | STING1 (0.36) | STING1HTR3EHTR3BHTR3AHTR3D | |
| Hydrochloric Acid SCHEMBL3494749 | 0.80 | STING1 (0.36) | STING1HTR3EHTR3BHTR3AHTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2268285-B1 | THERAPEUTIC COMPOUNDS | MERCK SHARP & DOHME (US) | 2018-06-27 | — | — | EP | disclosed |
| US-8591878-B2 | Therapeutic compounds | MERCK SHARP & DOHME CORP. (US) | 2013-11-26 | — | — | US | disclosed |
| US-8309540-B2 | HCV NS3 protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-11-13 | — | — | US | disclosed |
| US-20100093779-A1 | HCV NS3 PROTEASE INHIBITORS | MERCK SHARP & DOHME LLC | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093779-A1 | HCV NS3 PROTEASE INHIBITORS | HAVCR2, GTF3C3, CTSC | STING1 872/4885HTR3E 2559/4885HTR3B 2432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.